Emergency Committee Holds Urgent Press Conference on Drug Pricing Reform on the 10th
Surging Oil Prices and Exchange Rates from Middle East Crisis Increase Industry Costs
Concerns Over Reduced R&D and Suspension of Some Drug Approvals
"Tran

The Emergency Response Committee for the Reform of the Drug Pricing System to Advance the Pharmaceutical and Bio-Industry (hereinafter referred to as "the Committee"), which includes the Korea Pharmaceutical and Bio-Pharma Manufacturers Association and the Korea Biomedicine Industry Association, officially demanded the launch of a joint public-private research effort on March 10, in opposition to the government's plan to lower drug prices.


An emergency press conference for the reform of the drug pricing system to advance the pharmaceutical and bio-industry is underway on the 10th at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul. Photo by Minjae Kwak

An emergency press conference for the reform of the drug pricing system to advance the pharmaceutical and bio-industry is underway on the 10th at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul. Photo by Minjae Kwak

View original image

On this day, the Committee held an emergency press conference in the main auditorium on the fourth floor of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul. The Committee stated, "If the government's proposal to reform the drug pricing system, including price reductions, is implemented as planned, it is necessary to jointly analyze the impact on public health and the industry's structure." The Committee proposed to the government the initiation of joint public-private research on three key issues.


The Committee was established immediately after the government announced its reform plan, including drug price reductions, at the end of November last year. Previously, the government unveiled its first reform of the drug pricing system in 13 years. If this reform, which focuses on lowering the price of generic drugs, is implemented, generic medicines—which currently receive 53% to 59% of the price of original drugs—will have to lower their prices to around 40%. The Committee has requested a reconsideration, arguing that enforced drug price reductions will lead to reduced investment in R&D and quality innovation, the collapse of the industry’s foundation, suspension of essential drug production, threats to public health, and job losses.


The Committee presented three joint research requests at the press conference: a comprehensive analysis of the impact of the drug pricing reform plan on public health and the industrial structure; an investigation into the surge in pharmaceutical sales agents (CSOs), actual commission payments, and proposals for system improvements to establish order in distribution; and the development of advanced sustainability measures for the industry that align with the national goal of becoming one of the world’s top five pharmaceutical and bio-industrial powers.


The Committee also cited the recent burden on industry costs caused by soaring international oil prices and exchange rates due to the Middle East crisis as additional justification. The Committee stated, "Especially given the extremely high dependency on overseas sources for pharmaceutical ingredients in Korea, the burden on the industry will be further aggravated by the current situation. If the government proceeds with a rapid and large-scale drug price reduction amid heightened global uncertainties, the industry will be pushed to the brink and find it increasingly difficult to endure."



The Committee plans to conduct a signature campaign involving employees of member companies and pharmaceutical professionals. The Committee emphasized, "We urge the government to accept the industry's request for joint research, deliver results within one year, and prepare implementation measures together. This will enhance the transparency and predictability of policy decisions and increase acceptance at the industry level."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing